Adiso Therapeutics, Inc. kajeno e phatlalalitse hore e phethetse ho ngolisoa ha sehlopha sa eona sa pele sa bakuli thutong ea bongaka ea Phase 1b e hlahlobang ADS051 (BT051), modulator ea molomo, e thibelang mala, e nyane ea molek'hule ea khoebo ea neutrophil le ts'ebetso, joalo ka kalafo e ka bang teng. bakeng sa bakuli ba nang le lefu la ho ruruha ha ulcerative (UC) ka mokhoa o itekanetseng ho isa ho o matla. Lintlha tse foufetseng li bontšitse hore dosing sehlopheng sena e bolokehile ebile e mamelloa hantle, e tšehetsa ho qalisoa ha ho ngolisoa ha sehlopha sa bobeli sa litekanyetso tse phahameng.
Phase ena ea 1b ke thuto e laoloang ka mokhoa o sa reroang, e sa boneng habeli, e laoloang ke placebo, ho bakuli ba nang le UC e sebetsang ka mokhoa o itekanetseng ho isa ho o matla (NCT05084261). Maikemisetso a mantlha a thuto ena ke polokeho le mamello ka sepheo sa bobeli sa pharmacokinetics, le merero ea tlhahlobo ea ho fokotsa li-biomarker tse amanang le neutrophil. Boithuto bona ba Mokhahlelo oa 1b bo latela boithuto ba lethal dose le le leng la 1a ho baithaopi ba phetseng hantle bo bonts'itseng hore ADS051 e thibetsoe ka maleng ntle le chefo e fokotsang lethal dose kapa liketsahalo tse mpe tse tebileng.
"Ho shebana le li-neutrophils ke leano le lecha la ho alafa pathophysiology ea lefu la ulcerative colitis. Thuto ena ea Phase 1b ke mohato o latelang oa ho hlahloba kamoo ADS051 e ka thibelang ka mokhoa o sireletsehileng le ka katleho litsela tsa bohlokoa tse tsejoang ho baka ho falla le ho kenya ts'ebetsong ea li-neutrophils ka colon moo ts'ebetso e matla ea ho ruruha ho UC e ntseng e tsoela pele. Thutong ena re tla sheba li-biomarkers tsa ts'ebetso ea meriana le matšoao a pele a ts'ebetso ea kliniki e ka fetolelang ho fokotseha ha ho ruruha ha li-colon le ho khothalletsa pholiso ea mucosal ho bakuli ba nang le UC e itekanetseng ho isa ho e boima, "ho boletse Scott Megaffin, Mookameli e Moholo, Adiso. "Ho tsoela pele ho nts'etsapele nts'etsopele ea bongaka ea ADS051 ke ea bohlokoa ha ho nahanoa ka tlhoko e sa fihlelleheng ea bakuli ba nang le UC ba nang le mekhoa e fokolang ea kalafo e thibelang mala e ikhethang e amanang le ho rekisoa ha neutrophil."
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- today announced that it has completed enrollment of its first cohort of patients in a Phase 1b clinical study evaluating ADS051 (BT051), an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation, as a potential treatment for patients with moderately-to-severely active ulcerative colitis (UC).
- This Phase 1b study is the next step in exploring how ADS051 may safely and effectively inhibit key pathways known to cause the migration and activation of neutrophils in the colon where the acute inflammatory process in UC is ongoing.
- In this study we will look for biomarkers of pharmacological activity and early signs of clinical activity that may translate into reductions in colonic inflammation and promote mucosal healing in patients with moderate-to-severe UC,”.
